+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of Roche Diagnostics ONLINE DAT II, a new generation of assays for the detection of drugs of abuse



Evaluation of Roche Diagnostics ONLINE DAT II, a new generation of assays for the detection of drugs of abuse



Journal of Analytical Toxicology 28(7): 593-598



A new generation of ONLINE assays has been developed that offers improved performance and enhanced ease of use. This family of assays is being applied to both the COBAS INTEGRA and Roche/Hitachi line of analyzers. The four ONLINE DAT II assays that were evaluated included cocaine (benzoylecgonine) (BE), methadone (MDN), opiates (OP), and tetrahydrocannabinol (THC). The BE assay has a dual cutoff (150/300 ng/mL) with a dynamic range from 0 to 5000 ng/mL. The MDN assay has a cutoff of 300 ng/mL with a dynamic range from 0 to 2000 ng/mL. The opiates assay has a 300 ng/mL cutoff with a 0 to 2000 ng/mL range and a 2000 ng/mL cutoff with a 0 to 8000 ng/mL range. The THC assay has 20, 50, and 100 ng/mL cutoffs with 0 to 100, 0 to 300, and 0 to 300 ng/mL dynamic ranges, respectively. The ranges of the intra-assay precision (coefficients of variation for n = 20) run in the semiquantitative mode are 2.3-7.5% for BE, 2.0-3.8% for MDN, 1.9-4.2% for OP, and 3.9-5.2% for THC. The intra-assay qualitative precision for all of the assays as calculated from absorbance values is generally higher than that of the intra-assay semiquantitative precision at the cutoff. The qualitative precision ranges between 0.4% and 3.1%. The standard curve stability defined for the COBAS INTEGRA systems for these reagents ranges from 35 to 68 days. The clinical sensitivity and specificity were compared to the OnLine generation I and CEDIA immunoassays, as well as gas chromatography-mass spectrometry (GC-MS). The results indicate that for each assay, the sensitivity and specificity were the same or greater when compared to the other two immunoassay technologies. The results of each assay also correlated very well (> 99%) when compared with GC-MS.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 048993094

Download citation: RISBibTeXText

PMID: 15516319


Related references

Evaluation of Roche Diagnostics Online(R) Dat Ii, a New Generation of Assays for the Detection of Drugs of Abuse. Journal of Analytical Toxicology 28(7): 593-598, 2004

Multicenter evaluation of the new Roche Carbamazepine OnLine TDM assay developed for use on Roche Diagnostics/Hitachi analyzer systems. Clinical Chemistry 50(6, Suppl S, Part 2): A128, 2004

Evaluation of Roche Online assay performance for drugs of abuse screening in urine on Hitachi 917 compared with Hitachi 717. Clinical Chemistry 45(6 Part 2): A120, 1999

Screening for Drugs of Abuse with the Roche Ontrak Assays. Journal of Analytical Toxicology 16(3): 172-175, 1992

Comparison of Roche Online and Syva EMIT assay kits for testing for drugs of abuse. American Journal of Clinical Pathology 99(3): 341, 1993

Multicenter Evaluations Of The Roche Online?? Tdm Assays For Use On Roche/hitachi Analyzer Systems. Therapeutic Drug Monitoring 27(2): 233-234, 2005

Validation of the Roche Abuscreen OnLine drug of abuse reagents on the Roche/Hitachi 917 analyzer. Clinical Chemistry 45(6 Part 2): A125-A126, 1999

Comparison of drugs of abuse screening by thin layer chromatography vs emit dau immunoassay as performed on the roche cobas bio and the em diagnostics epos. Clinical Chemistry: 934, 1985

Evaluation of the Unicel (TM) DXC 600 (Beckman Coulter) and comparison with Integra 800 (R) (Roche Diagnostics') FT Evaluation des performances analytiques du systeime Unicel (TM) DXC avec l'Integra 8000 (Roche diagnostics (R)). 2007

Evaluation of first- and second-generation assays for detection of antibody to hepatitis C virus in non-A, non-B chronic liver diseases--evaluation of 1st and 2nd-generation assays in NANBH. Kurume Medical Journal 40(1): 27-32, 1993

Comparison of CEDIA and ONLINE drugs of abuse assays. Clinical Chemistry 41(S6 Part 2): S125, 1995

Evaluation of the Roche Diagnostics LightCycler-Apo B 3500 Mutation Detection Kit. Clinical Chemistry and Laboratory Medicine 38(7): 667-671, 2000

Multicenter evaluation of Roche Diagnostics homogeneous enzymatic LDL-c plus assay on the Roche/Hitachi analyzers. Clinical Chemistry 45(6 Part 2): A10, 1999

Precision and comparability of Abuscreen OnLine assays for drugs of abuse screening in urine on Hitachi 917 with other immunochemical tests and with GC/MS. Clinical Laboratory 46(1-2): 49-52, 2000

Evaluation of the triage panel for drugs of abuse test for the simultaneous detection of 7 drugs of abuse. Clinical Chemistry 38(6): 1014, 1992